Previously published studies have indicated that antimetastatic effects of Zol correlate with that tumour cell expression of the transcription factor MAF (28), whereas other studies have shown that high expression of GIPC1 and CAPG is associated with antitumour activity of Zol in breast cancer patients (24). This evidence concerns the gene GIPC1 and breast carcinoma.